Cargando…
Laboratory assessment of rivaroxaban: a review
Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of which greatly decreases thrombin generation. Based on the results of phase III clinical trials,...
Autores principales: | Samama, Meyer Michel, Contant, Geneviève, Spiro, Theodore E, Perzborn, Elisabeth, Le Flem, Lena, Guinet, Céline, Gourmelin, Yves, Rohde, Gabriele, Martinoli, Jean-Luc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3726412/ https://www.ncbi.nlm.nih.gov/pubmed/23822763 http://dx.doi.org/10.1186/1477-9560-11-11 |
Ejemplares similares
-
The discovery of rivaroxaban: translating preclinical assessments into clinical practice
por: Kubitza, Dagmar, et al.
Publicado: (2013) -
Effects of Rivaroxaban on Platelet Activation and Platelet–Coagulation Pathway Interaction: In Vitro and In Vivo Studies
por: Perzborn, Elisabeth, et al.
Publicado: (2015) -
Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo
por: Perzborn, E, et al.
Publicado: (2014) -
International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
por: Beyer-Westendorf, Jan, et al.
Publicado: (2019) -
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the
MAGELLAN Study
por: Spyropoulos, Alex C., et al.
Publicado: (2019)